Evidence map›Paper›PMID 24741445›Full record

ReviewScientifica2014

Human interferon alpha-2b: a therapeutic protein for cancer treatment.

Ratih Asmana Ningrum

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Scientifica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 123 citations in OpenAlex.

  1. Article
  2. Metabolic engineering ofApplied and environmental microbiology · 2026
    Review
  3. Article
  4. Article
  5. Case-based review: Craniopharyngioma treated with intracystic peginterferon.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. An Updated Review of the Therapeutic Management of Keratoacanthomas.The Journal of clinical and aesthetic dermatology · 2022
    Review
  19. An Updated Review of the Therapeutic Management of Keratoacanthomas.The Journal of clinical and aesthetic dermatology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ratih Asmana NingrumResearch Center for Biotechnology, Cibinong Science Center, Jalan Raya Bogor km 46, Cibinong, Bogor, West Java 16911, Indonesia.
Indonesian Institute of Sciences · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human interferon alpha (hIFNα) is a wide biological activity cytokine that is used in hepatitis and cancer treatments. It regulates many genes that are involved in antiviral and antiproliferative activities. This mini review focuses on human interferon alpha-2b (hIFNα-2b) as therapeutic protein for cancer treatment. The review covers hIFNα-2b molecular characteristic and its molecular mechanism by Janus activated kinase/signal transducer activation of transcription (JAK-STAT) pathway. The JAK-STAT pathway regulates not only proteins involved in inhibition of proliferation but also apoptosis. As additional discussion of clinical applications, the use of recombinant hIFNα-2b (rhIFNα-2b) as therapeutic protein in several types of cancer is also explained.

Identifiers

PMID24741445
PMCPMC3967813
OpenAlexW2050176787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.